Cord Blood America CEO Matthew Schissler to Be Interviewed on MoneyTV; Discussed Third Quarter Performance and Recent Acquisitions

Cord Blood America CEO Matthew Schissler to Be Interviewed on MoneyTV; Discussed Third Quarter Performance and Recent Acquisitions

LOS ANGELES, Nov. 16 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (BULLETIN BOARD: CBAI) , the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com/ ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, announced today that its CEO, Matthew Schissler, will appear on the popular MoneyTV program on Saturday and Sunday, Nov. 18-19, in an interview on the Company's achievements and future business prospects.

MoneyTV is a nationally syndicated TV program that is broadcast to more than 40 million television, cable TV and DISH network homes in the U.S. It is also broadcast to 42 million TV homes in Western Europe and is carried on NBC-TV in the Virgin Islands and Puerto Rico. The show can also be viewed at http://www.moneytv.net/ . A complete menu of TV listings for the program is available at the MoneyTV web site.

MoneyTV features interviews with the senior management of publicly traded companies. Viewers include individual investors as well as Wall Street professionals, including representatives of buy-side and sell-side firms. These members of the financial community include brokers, investment bankers, portfolio and fund managers, representatives of family offices, investment advisors, financial planners and analysts.

"We are pleased with this opportunity to continue to tell the exciting Cord Blood America story to the investment community," said Mr. Schissler. "MoneyTV has the reach and the clout with the investing public, both national and internationally, to be an important vehicle for this interview."

About Cord Blood America

Cord Blood America (BULLETIN BOARD: CBAI) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (BULLETIN BOARD: CBAI) , visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

CONTACT:
Paul Knopick
E & E Communications
949/707-5365
pknopick@eandecommunications.com

Source: Cord Blood America, Inc.

CONTACT: Paul Knopick of E & E Communications, +1-949-707-5365,
pknopick@eandecommunications.com, for Cord Blood America, Inc.

Web site: http://www.moneytv.net/

Web site: http://www.corcell.com/

Web site: http://www.cordblood-america.com/

-------
Profile: intent